Equities research analysts expect Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) to report earnings per share (EPS) of ($0.57) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Kiniksa Pharmaceuticals’ earnings, with estimates ranging from ($0.60) to ($0.54). Kiniksa Pharmaceuticals reported earnings per share of ($0.88) during the same quarter last year, which indicates a positive year over year growth rate of 35.2%. The company is expected to issue its next earnings report on Thursday, March 5th.
On average, analysts expect that Kiniksa Pharmaceuticals will report full year earnings of ($2.99) per share for the current fiscal year, with EPS estimates ranging from ($3.02) to ($2.96). For the next financial year, analysts forecast that the firm will report earnings of ($2.63) per share, with EPS estimates ranging from ($2.76) to ($2.50). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Monday, October 28th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.23.
Several research firms have weighed in on KNSA. Goldman Sachs Group upgraded Kiniksa Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the company from $16.00 to $18.00 in a report on Friday, December 6th. Zacks Investment Research cut Kiniksa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Finally, ValuEngine cut Kiniksa Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $21.75.
NASDAQ KNSA traded down $0.17 during trading on Friday, hitting $15.45. 451,621 shares of the stock traded hands, compared to its average volume of 298,595. The company has a market capitalization of $857.19 million, a P/E ratio of -4.65 and a beta of -0.95. The firm has a 50-day simple moving average of $12.37 and a 200-day simple moving average of $10.26. Kiniksa Pharmaceuticals has a 12-month low of $5.01 and a 12-month high of $25.79.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. lifted its stake in shares of Kiniksa Pharmaceuticals by 300.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 140,000 shares of the company’s stock valued at $1,191,000 after purchasing an additional 105,000 shares during the last quarter. State Street Corp lifted its stake in shares of Kiniksa Pharmaceuticals by 4.2% in the 3rd quarter. State Street Corp now owns 229,477 shares of the company’s stock valued at $1,953,000 after purchasing an additional 9,282 shares during the last quarter. First Manhattan Co. lifted its stake in shares of Kiniksa Pharmaceuticals by 68.3% in the 2nd quarter. First Manhattan Co. now owns 63,976 shares of the company’s stock valued at $866,000 after purchasing an additional 25,970 shares during the last quarter. Citadel Advisors LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 195.8% in the 2nd quarter. Citadel Advisors LLC now owns 372,287 shares of the company’s stock valued at $5,041,000 after purchasing an additional 246,442 shares during the last quarter. Finally, Morgan Stanley lifted its stake in shares of Kiniksa Pharmaceuticals by 54.2% in the 2nd quarter. Morgan Stanley now owns 60,098 shares of the company’s stock valued at $814,000 after purchasing an additional 21,130 shares during the last quarter. Institutional investors and hedge funds own 29.85% of the company’s stock.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Further Reading: Google Finance Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.